Related Experiment Video

Updated: Mar 13, 2026

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

7.3K

Role of BET proteins in castration-resistant prostate cancer

Ester Fernandez-Salas1, Shaomeng Wang2, Arul M Chinnaiyan3

  • 1Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA; Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI 48109, USA.

Drug Discovery Today. Technologies
|October 23, 2016
PubMed

Insights

Castration resistant prostate cancer (CRPC) has limited treatment options. BET-bromodomain inhibitors show promise in preclinical models and clinical trials for CRPC by targeting key transcription regulators.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Castration resistant prostate cancer (CRPC) presents a significant clinical challenge, especially when second-generation anti-androgen therapies fail.
  • The AR-transcriptional program is crucial in CRPC progression.
  • BET-bromodomain (BET-BRD) readers are identified as key regulators of AR-, ERG-, and c-Myc-mediated transcription in CRPC.

Purpose of the Study:

  • To investigate the therapeutic potential of BET-BRD inhibitors in castration resistant prostate cancer.
  • To evaluate the role of BET-BRD readers in CRPC pathogenesis.

Main Methods:

  • Preclinical studies using CRPC models.
  • Evaluation of BET-BRD inhibitors in clinical trials.

Main Results:

  • BET-BRD inhibitors demonstrated significant pre-clinical efficacy in CRPC models.
  • Ongoing clinical trials are evaluating the safety and efficacy of these novel agents.

Conclusions:

  • BET-BRD inhibitors represent a promising novel therapeutic strategy for CRPC.
  • These inhibitors target key transcriptional regulators implicated in CRPC progression.
  • Further clinical evaluation is warranted to establish their role in patient treatment.

More Related Videos

Murine Prostate Micro-dissection and Surgical Castration08:49

Murine Prostate Micro-dissection and Surgical Castration

Published on: May 11, 2016

48.0K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

14.0K

Related Concept Videos

Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
38.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K